Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
about
Trial Watch-Immunostimulation with cytokines in cancer therapyNivolumab in combination with ipilimumab for the treatment of melanoma.Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic MetastasesComparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes.
P2860
Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@ast
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@en
type
label
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@ast
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@en
prefLabel
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@ast
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@en
P2093
P2860
P1476
Single Institution Experience ...... M-CSF) in Metastatic Melanoma.
@en
P2093
Anita Giobbie-Hurder
F Stephen Hodi
Hilary Donahue
Jason J Luke
Meredith Davis
Mizuki Nishino
Nancy Bailey
Patrick A Ott
P2860
P304
P356
10.1158/2326-6066.CIR-15-0066
P577
2015-05-05T00:00:00Z